FIGURE 6.

The constructed aging risk signature for evaluating ICI treatment efficacy. A, ICI prognosis difference was noticed between low‐risk and high‐risk subgroups under the urothelial cancer (UC) immunotherapy cohort. B, Multivariate‐adjusted Cox analysis was conducted to obtain the real association of aging risk signature with ICI survival outcome. C, Distinct objective response rate and (D) disease control rate were observed in 2 risk subpopulations. E, Quantification of the enrichment of immune response or immunotherapy efficacy‐relevant signatures in low‐risk and high‐risk subgroups with the data from the UC cohort. GSEA analysis of low‐risk patients with annotation pathways from (F) KEGG and (G) GO databases. *P < .05, **P < .01, ***P < .001